Derivatives and Quantitative Strategist

Gaudenz Schneider

Equity Bottom-Up

Fisher & Paykel Healthcare Cor / Equity Bottom-Up

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed Inc (RMD AU)</a> price-ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long Fisher &amp; Paykel Health (FPH AU) and short ResMed Inc (RMD AU) targets a 7% return. However, ResMed is more attractively valued on PEG ratio basis.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Health (FPH AU) vs. ResMed Inc (RMD AU) price-ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long Fisher &amp; Paykel Health (FPH AU) and short ResMed Inc (RMD AU) targets a 7% return. However, ResMed is more attractively valued on PEG ratio basis.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

<ul>
<li>
Context: Friday’s sell-off occurred after the Australian market closed, but several ASX-listed companies were swept up in the decline through dual listings or U.S.-traded ADRs.</li>
<li>
This Insight looks at the impact on prominent <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200</a> constituents — including BHP, CSL, and major banks. While some companies showed limited movement, others, such as BHP, experienced sharper declines.</li>
<li>
Why Read: Understand where the Australian market might be headed when trading resumes after the weekend.</li>
</ul>



Context: Friday’s sell-off occurred after the Australian market closed, but several ASX-listed companies were swept up in the decline through dual listings or U.S.-traded ADRs.

This Insight looks at the impact on prominent S&amp;P/ASX 200 constituents — including BHP, CSL, and major banks. While some companies showed limited movement, others, such as BHP, experienced sharper declines.

Why Read: Understand where the Australian market might be headed when trading resumes after the weekend.


BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Healthcare (FPH AU) vs. ResMed (RMD AU) Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth, profitability, and operational efficiency.</li><li>The company's focused growth across its core business segments has yielded a reported 11% revenue increase, attributed to robust demand for sleep health, breathing devices, masks, accessories, and residential care software offerings, spanning across global markets.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth, profitability, and operational efficiency.The company's focused growth across its core business segments has yielded a reported 11% revenue increase, attributed to robust demand for sleep health, breathing devices, masks, accessories, and residential care software offerings, spanning across global markets.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

<ul><li>ResMed recently reported its fourth quarter results for the fiscal year 2024, providing a comprehensive update on its performance across various business segments.</li><li>The company demonstrated robust growth attributed to increased demand and operational excellence, with a focus on innovations in sleep apnea, digital health solutions, and home medical equipment software.</li><li>Financially, ResMed achieved a 9% increase in revenue year-over-year, amounting to $1.22 billion for the quarter.</li></ul>

ResMed recently reported its fourth quarter results for the fiscal year 2024, providing a comprehensive update on its performance across various business segments.The company demonstrated robust growth attributed to increased demand and operational excellence, with a focus on innovations in sleep apnea, digital health solutions, and home medical equipment software.Financially, ResMed achieved a 9% increase in revenue year-over-year, amounting to $1.22 billion for the quarter.

ResMed Inc.: A Story Of Increased Market Penetration and New Patient Acquisition! - Major Drivers

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ResMed (RMD UN)

Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

The price-ratio between Fisher & Paykel Health and ResMed has diverged by 2 standard deviations, offering a potential relative value opportunity...

Gaudenz Schneider

BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

Friday’s U.S. market rout pushed dual-listed Australian stocks lower, with BHP and Woodside among the biggest movers. US-traded ADRs and futures...

Gaudenz Schneider

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth,...

Baptista Research

ResMed Inc.: A Story Of Increased Market Penetration and New Patient Acquisition! - Major Drivers

ResMed recently reported its fourth quarter results for the fiscal year 2024, providing a comprehensive update on its performance across various...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

The price-ratio between Fisher & Paykel Health and ResMed has diverged by 2 standard deviations, offering a potential relative value opportunity...

Gaudenz Schneider

BHP (BHP AU/US) And Woodside (WDS AU/US) Slide as U.S. Sell-Off Spills Into Australian Stocks

Friday’s U.S. market rout pushed dual-listed Australian stocks lower, with BHP and Woodside among the biggest movers. US-traded ADRs and futures...

Gaudenz Schneider

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

​FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth,...

Baptista Research

ResMed Inc.: A Story Of Increased Market Penetration and New Patient Acquisition! - Major Drivers

ResMed recently reported its fourth quarter results for the fiscal year 2024, providing a comprehensive update on its performance across various...

Baptista Research

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.